The grant, awarded through the small business innovation research (SBIR) program, will support phase II safety and efficacy studies of PMI-150 in a multicenter, randomized, double blind, and placebo-controlled clinical trial in patients suffering from episodic acute moderate-to-severe pain.
The company used an earlier SBIR grant to conduct a 20-patient phase I pilot study of the drug that established proof of principle for intranasal administration of ketamine for the treatment of episodic breakthrough pain in patients taking opioid analgesics for chronic pain.
“Javelin is honored by our success in this highly competitive grant process from such a prestigious source,” said Dr Daniel Carr, the company’s CEO and chief medical officer.